<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01699152</url>
  </required_header>
  <id_info>
    <org_study_id>TG02-102</org_study_id>
    <nct_id>NCT01699152</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma</brief_title>
  <official_title>Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tragara Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tragara Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, dose escalation study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine the highest dose of TG02 citrate that can be safely&#xD;
      given to patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>28 days</time_frame>
    <description>To assess the number of patients with dose-limiting toxicities (DLT) and the dose of TG02 citrate that can be safely given to patients with CLL or SLL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>The number of patients with adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>TG02 citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG02 citrate capsules given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG02 citrate</intervention_name>
    <description>TG02 citrate capsules</description>
    <arm_group_label>TG02 citrate</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed Chronic Lymphocytic Leukemia Small&#xD;
             Lymphocytic Lymphoma.&#xD;
&#xD;
          -  Patients must meet one or more of the following indications for treatment:&#xD;
&#xD;
               1. Progressive disease or marked splenomegaly and/or lymphadenopathy.&#xD;
&#xD;
               2. Anemia (hemoglobin &lt;11 mg/dL) or thrombocytopenia (platelets&lt;100,000/μL).&#xD;
&#xD;
               3. Unexplained weight loss exceeding 10% of body weight over the previous 6 months.&#xD;
&#xD;
               4. CTCAE Grade 2 or 3 fatigue.&#xD;
&#xD;
               5. Fevers &gt;100.5º F or night sweats for more than 2 weeks without evidence of&#xD;
                  infection.&#xD;
&#xD;
               6. Progressive lymphocytosis, with an increase exceeding 50% over a 2 month period&#xD;
                  or a doubling time of less than 6 months.&#xD;
&#xD;
               7. Need for cytoreduction prior to allogeneic stem cell transplant.&#xD;
&#xD;
          -  Patients must have relapsed or refractory disease after ≥1 prior line of treatment.&#xD;
&#xD;
          -  The interval from prior treatment to time of study drug administration should be at&#xD;
             least 5 half-lives for cytotoxic and noncytotoxic agents.&#xD;
&#xD;
          -  Low-dose corticosteroids (prednisone &lt;20 mg/ day or equivalent dose) are permitted&#xD;
             throughout study.&#xD;
&#xD;
          -  Clinically significant toxicities from prior chemotherapy must be resolved to Grade ≤&#xD;
             1.&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
          -  ECOG performance status ≤2.&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  absolute neutrophil count &gt;1,000/μL in absence of bone marrow involvement&#xD;
&#xD;
               -  platelets ≥30,000/μL in absence of bone marrow involvement&#xD;
&#xD;
               -  If patient has extensive bone marrow involvement, minimum ANC and platelet levels&#xD;
                  are not required.&#xD;
&#xD;
               -  total bilirubin ≤1.5 X institutional ULN unless due to Gilbert's syndrome,&#xD;
                  controlled autoimmune hemolytic anemia or immune thrombocytopenia&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt;2.5 X institutional ULN unless due to disease&#xD;
&#xD;
               -  creatinine &lt;2.0 mg/dL OR creatinine clearance &gt;50 mL/min/1.73 m2&#xD;
&#xD;
          -  Negative serum or urine pregnancy test at the time of first dose for WOCBP.&#xD;
&#xD;
          -  Ability to understand the requirements of the study, provide written informed consent&#xD;
             and authorization of use and disclosure of protected health information, and agree to&#xD;
             abide by the study restrictions and to return for required assessments.&#xD;
&#xD;
          -  Ability to take oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study or those who have not&#xD;
             recovered from adverse events (CTCAE Grade &gt; 1) due to agents administered more than 3&#xD;
             weeks earlier.&#xD;
&#xD;
          -  Patients who have received prior treatment with a CDK inhibitor within 12 months of&#xD;
             study enrollment.&#xD;
&#xD;
          -  High-dose corticosteroids (prednisone ≥20mg/day or equivalent dose) must be&#xD;
             discontinued ≥ 7 days of initiating therapy.&#xD;
&#xD;
          -  Patients with known central nervous system involvement.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition as TG02 citrate.&#xD;
&#xD;
          -  Patients with G6PD deficiency.&#xD;
&#xD;
          -  Concurrent severe or uncontrolled medical disease (including but not limited to&#xD;
             history of ventricular arrhythmia or symptomatic conduction abnormality within 12&#xD;
             months, ongoing or active systemic infection, diabetes, hypertension, coronary artery&#xD;
             disease, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or&#xD;
             psychiatric illness/social situations) that, in the opinion of the Investigator, would&#xD;
             compromise the safety of the patient or compromise the ability of the patient to&#xD;
             complete the study.&#xD;
&#xD;
          -  Pregnant and/or breast-feeding women.&#xD;
&#xD;
          -  Prior or second malignancy, except for adequately treated basal cell or squamous cell&#xD;
             skin cancer, in situ cervical or breast cancer, or other cancer for which the subject&#xD;
             has received curative therapy at least 3 years prior to study entry.&#xD;
&#xD;
          -  Known HIV or AIDs.&#xD;
&#xD;
          -  QTc interval prolongation &gt;450ms for males and &gt;470 ms for females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T Parrott</last_name>
    <role>Study Director</role>
    <affiliation>Tragara Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GRU</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MDACC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 1, 2012</study_first_submitted>
  <study_first_submitted_qc>October 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

